15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 学术讨论& HBV English NZ发现有助于节省了400万人的生命乙肝
查看: 1290|回复: 4
go

NZ发现有助于节省了400万人的生命乙肝 [复制链接]

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

1
发表于 2015-9-6 08:41 |只看该作者 |倒序浏览 |打印
Exclusive: Kiwi discovery could help save lives of 400 million people with hepatitis B
Wed, Sep 2
share
Lorelei Mason


ONE News Reporter

New Zealand researchers have made a discovery which could potentially save the lives of many of the four hundred million people living with hepatitis B worldwide.
New Zealand researchers make potentially life-saving Hepatitis B discovery
02:29
Kiwi scientists have discovered a vital DNA marker related to the chronic disease that affects 400 million people worldwide.
Source: ONE News

They've identified a key DNA marker in the blood to help determine which patients with chronic hepatitis B are likely to go on to get liver cancer or die from other liver-related conditions.

The Health Research Council-funded study, led by Auckland City Hospital hepatologist Professor Ed Gane, followed up with 570 patients from Kawerau in the Bay of Plenty who were diagnosed with chronic hepatitis B in 1984.
Advertisement

These patients were part of the Hepatitis Foundation of New Zealand's pioneering Kawerau Community Study, led by Mr Alexander (Sandy) Milne, MBE.

Milne, a lab technician, was alarmed at the epidemic levels of the virus he was seeing in localised areas of the country and the high rates of liver cirrhosis and cancer the virus was causing.

He went on to establish the Hepatitis Foundation which first tested 97 per cent of Kawerau's 9000 residents for the virus. Half of them tested positive. New Zealand was found to have one of the highest rates of Hepatitis B in the developed world. Milne’s work later saw New Zealand become the first sovereign nation in the world to offer free vaccinations to babies to prevent the virus.

Professor Gane and his co-investigators analysed blood serum collected from the Kawerau study cohort. The serum was perfectly preserved having been stored in freezers and meticulously maintained at minus 20 degrees centigrade for nearly 30 years. The research team then followed up with all survivors of the Kawerau study between October 2011 and November 2013, collecting blood samples and checking for signs of liver disease.

That research has now identified exactly which of those study patients will go on to develop liver cancer and cirrhosis by examining levels of hepatitis B virus in their blood samples.

"Levels of the hepatitis B virus in the blood greater than 100,000 viruses per millilitre of blood, is a predictor for developing problems long-term" Professor Gane says.

"It also found that people who were older when they were first followed and Maori were also more at risk of developing complications," he says.

As a result of the research team's findings, every patient on New Zealand's current national community-based surveillance programme will soon have their baseline hepatitis B virus DNA levels recorded. Those patients with high virus DNA levels will receive increased surveillance for liver cancer.

Kawerau father Klyjah Peters is one of those patients. He was first diagnosed with the virus as a six year old in 1984. Study nurse Helen Purcell has monitored his health regularly since with bi-annual blood tests. Peters was recently found to have early stage cirrhosis of the liver which is being successfully treated with drugs to prevent its spread.

"Hopefully I'm around much longer for my kids and grandkids" says Peters.

"If we're able to say at an early stage that a particular person's at risk for liver cancer then we can put them into more intensive follow-up so we can pick up the liver cancer at a very early stage," says Professor Gane.
Advertisement

About 2 billion people worldwide have been infected with the hepatitis B virus and about 400 million people have chronic hepatitis B, of whom almost 40 per cent will die from complications.  

"Nearly a million people a year die from liver cancer from hepatitis B, mainly in the Asia and Pacific region. Only one carcinogen kills more people than hepatitis B and that’s tobacco, so it’s a huge health burden," says Professor Gane.

Currently about 100,000 people in New Zealand are chronically infected with the hepatitis B virus.


Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

2
发表于 2015-9-6 08:41 |只看该作者
本帖最后由 StephenW 于 2015-9-6 08:41 编辑

独家:猕猴桃发现有助于节省了400万人的生命乙肝
星期三,9月2日
共享
罗蕾莱梅森


ONE讯记者

新西兰研究人员做了一个发现这有可能挽救许多四百万人生活在全球乙肝的生命。
新西兰研究人员让可能挽救生命的乙肝发现
02:29
新西兰科学家发现相关的慢性疾病,影响4亿人在全球一个重要的DNA标记。
来源:ONE新闻

他们已经确定了关键的DNA标记在血液中,以帮助确定哪些患者有慢性乙肝有可能继续得到肝癌或其它肝脏相关情况死亡。

健康研究委员会资助的研究,带领由奥克兰市医院肝病专家教授埃德甘恩,随访570例患者卡韦劳在丰盛湾谁被诊断为慢性乙型肝炎于1984年。
广告

这些患者新西兰先驱卡韦劳社区研究的肝炎基金会的带动下,亚历山大先生(桑迪)米尔恩,MBE的一部分。

米尔恩,实验室技术员,感到震惊,他看到在该国的局部地区,肝硬化和癌症的高利率的病毒引起的病毒流行的程度。

他接着建立肝炎基金会这第一次测试卡韦劳的9000居民的97%的病毒。其中一半呈阳性。新西兰被发现有乙型肝炎在发达世界最高的国家之一。米尔恩的工作后来看到新西兰成为第一个主权国家在世界上提供免费接种疫苗的婴儿,以防止病毒。

甘恩教授和他的同事调查分析了卡韦劳研究组采集血清。将血清保存完好的已经被存储在冰柜和精心维持在零下20摄氏度了近30年。该研究小组随后跟进的卡韦劳研究2011年10月和2013年11月间的所有幸存者,采集血样,并检查肝脏疾病的征兆。

现在的研究确定到底是哪那些研究的患者将继续通过检查他们的血液样品中的B型肝炎病毒的水平发展肝癌和肝硬化。

“乙肝病毒在血液中的每毫升血液大于100,000病毒水平,是发展问题,长期的预测”甘恩教授说。

“调查还发现,人谁是老年人,他们首先遵循和毛利人也更是发展并发症的危险的时候,”他说。

作为该研究小组的调查结果,在新西兰的现行国家以社区为基础的监控方案每个病人很快就会有自己的底线乙肝病毒DNA水平记录。这些患者的高病毒DNA水平将得到肝癌加强监督。

卡韦劳父亲Klyjah彼得斯是其中的一个病人。他首先被诊断出患有这种病毒在1984年研究护士海伦·赛尔一个六岁起与两年一度的验血一直定期监测自己的健康。彼得斯最近被发现有正在被成功地使用药物治疗,以防止其蔓延肝早期肝硬化。

“希望我在周围更长的时间为我的孩子和孙子们”彼得斯说。

“如果我们能够在早期阶段的说,一个特定的人在危险中为肝癌,然后我们就可以把它们放到更深入的跟进,所以我们可以拿起肝癌在一个非常早期的阶段,”甘恩教授说: 。
广告

大约2十亿世界人民已经感染了乙肝病毒,约有4亿人患有慢性乙肝,其中近40%将死于并发症。

“近百万人每年死于肝癌由乙肝,主要集中在亚洲和太平洋地区只有一个致癌物质杀死更多的人比乙肝病毒,烟草,所以这是一个巨大的健康负担,”甘恩教授说。

目前,大约10万人在新西兰慢性感染了乙肝病毒。

Rank: 5Rank: 5

现金
723 元 
精华
帖子
493 
注册时间
2015-4-23 
最后登录
2019-6-26 
3
发表于 2015-9-7 16:31 |只看该作者
不知所以然

Rank: 8Rank: 8

现金
2711 元 
精华
帖子
1561 
注册时间
2009-1-4 
最后登录
2024-5-2 
4
发表于 2015-9-8 22:17 |只看该作者
好像有点题不达意

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

5
发表于 2015-9-9 09:44 |只看该作者
回复 默然10 的帖子

是的,难以理解.
发现是:
“乙肝病毒在血液中的每毫升大于100,000 (100,000 copies/ml)水平,是发展长期问题的预测”甘恩教授说。
甘恩(Gane)教授,很受人尊敬的新西兰研究员,他的说法基于血液样本高达30年历史, 加上后续,达成上述结论.

因此,如果病毒载量 > 100,000 copies (20,000 iu)/ml应小心
‹ 上一主题|下一主题
你需要登录后才可以回帖 登录 | 注册

肝胆相照论坛

GMT+8, 2024-5-24 13:29 , Processed in 0.029222 second(s), 11 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.